Roche says adding Actemra to remdesivir does not reduce Covid-19 hospitalisation
The trial combining the rheumatoid arthritis drug with the anti-viral had disappointing results with regard to Covid-19 pneumonia
11 March 2021 - 14:39
Zurich — Swiss drugmaker Roche said on Thursday that adding its drug Actemra to Gilead Sciences’ Veklury medication, made of remdesivir, did not reduce hospital stays for patients with severe Covid-19 pneumonia.
Roche’s anti-inflammatory Actemra combined with Veklury, Gilead’s ant-iviral drug, failed to reduce hospitalisation durations in the Remdacta trial, which compared the cocktail with treatment using only Veklury and standard care, Roche said...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.